Search clinical trials for: RAD001 and MitomycinC

Total 270369 results

Seoul National University Hospital

Completed

Study of RAD001 in Adenoid Cystic Carcinoma (ACCRAD001)

Adenoid Cystic Carcinoma

Korea, Republic of
Austin Health

Unknown

Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol (RADiChol)

Cholangiocarcinoma

Australia
Sheba Medical Center

Unknown

Phase II Study of RAD001 in a Neoadjuvant Setting in Men With Intermediate or High Risk Prostate Cancer

Prostate Cancer

Israel
Mayo Clinic
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Radiation Therapy, and Sargramostim Before and After Surgery in Treating Patients With Soft Tissue Sarcoma That Can Be Removed By Surgery

Sarcoma | Metastatic Cancer
Southern Europe New Drug Organization
Bayer; Novartis

Suspended

Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets

Advanced Solid Tumors

Italy
Reneo Pharma Ltd

Completed

A Phase 1b Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders

Fatty Acid Oxidation Disorders

United States, France, Spain
KalVista Pharmaceuticals, Ltd.
Juvenile Diabetes Research Foundation

Completed

A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME

Diabetic Macular Edema

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

Stage III Bladder Cancer AJCC v8 | Stage III Renal Pelvis Cancer AJCC v8 | Stage III Ureter Cancer AJCC v8 | Stage III Urethral Cancer AJCC v8 | Stage IIIA Bladder Cancer AJCC v8 | Stage IIIB Bladder Cancer AJCC v8 | Urethral Urothelial Carcinoma | Stage II Bladder Cancer AJCC v8 | Stage II Renal Pelvis... and other conditions

United States
University of Chicago
Novartis

Completed

Exploratory Study Evaluating Fluorodeoxyglucose - Position Emission Tomography as a Predictive Marker for Therapy With RAD001 in Metastatic Renal Cell Cancer

Carcinoma, Renal Cell

United States
Seoul National University Hospital

Completed

RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)

Renal Cell Carcinoma

Korea, Republic of
Dana-Farber Cancer Institute
Novartis; Pediatric Oncology Experimental Therapeutics Investigators' Consortium

Completed

Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas

Glioma | Astrocytoma | Low-grade Glioma

United States
Massachusetts General Hospital
Novartis; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center

Completed

RAD001 in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver

Metastatic Cancer | Liver Cancer

United States
Jenny C. Chang, MD
The Methodist Hospital Research Institute

Completed

NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer (NECTAR)

Breast Cancer | Triple Negative Breast Cancer

United States
Novartis Pharmaceuticals

Completed

Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer

Metastatic Renal Cell Carcinoma

China
Asan Medical Center

Completed

RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression

Stomach Neoplasm

Korea, Republic of
Hellenic Cooperative Oncology Group
Novartis

Terminated

Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors

Gastrointestinal Tumors | Pancreatic Neuroendocrine Tumors | Pancreatic Tumors | Gastrointestinal Neuroendocrine Tumors

Greece
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)

Plexiform Neurofibroma Associated With Neurofibromatosis Type 1

Israel
Bayside Health

Unknown

Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Australia
Novartis Pharmaceuticals

Terminated

Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Glioblastoma Multiforme

United States
Asan Medical Center

Completed

RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment

Stomach Neoplasm

Korea, Republic of
Samsung Medical Center

Completed

Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors

Solid Tumor

Korea, Republic of
Baylor College of Medicine
Novartis Pharmaceuticals

Withdrawn

Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)

Sturge Weber Syndrome

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Terminated

Study of RAD001 in Soft Tissue Extremity and/or Retroperitoneal Sarcomas

Sarcoma

United States
University Hospital Inselspital, Berne
University of Bern; Hospital Centre Biel/Bienne

Recruiting

Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids

Bladder Cancer | Non-muscle Invasive

Switzerland
University of Florida
Ocean Spray, Inc.

Completed

The Effect of a Cranberry Beverage on Intestinal Permeability and Gastrointestinal Function in Generally Healthy Adults (MAC)

Intestinal Permeability | Gastrointestinal Function

United States
Daniel George, MD
Novartis; Pfizer

Completed

A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma (Rad/Sutent)

Renal Cell Carcinoma

United States
Fox Chase Cancer Center

Active, not recruiting

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Urothelial Carcinoma of the Bladder

United States
KalVista Pharmaceuticals, Ltd.

Completed

Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)

Diabetic Macular Edema

United States
Medical Research Council
European Organisation for Research and Treatment of Cancer - EORTC

Completed

Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer

Lung Cancer

United Kingdom
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center; Massachusetts General Hospital; Novartis; MOUNT SINAI...

Completed

RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

Thyroid Cancer

United States
Novartis Pharmaceuticals

Completed

Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

Breast Neoplasms | Neoplasm Metastasis

Belgium, Italy, Poland, Sweden, France
Novartis Pharmaceuticals

Completed

Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients

Small-Cell Lung Cancer

United States, France
Mustafa Sahin
Novartis Pharmaceuticals; Autism Speaks; Tuberous Sclerosis Alliance; Seizure Tracker...

Completed

Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC) (TSC)

Tuberous Sclerosis Complex

United States
Linda C. Higgins
University of Texas Southwestern Medical Center

Terminated

Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal

Kidney Cancer

United States
Academisch Medisch Centrum - Universiteit van Amsterdam...
Erasmus Medical Center

Withdrawn

Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome (EVAMP)

Neoplasm Metastasis | Neoplastic Processes | Peutz-Jeghers Syndrome

Netherlands
Boston Children's Hospital
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Completed

RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome

PTEN Gene Mutation | PTEN Hamartoma Tumor Syndrome

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.

Renal Angiomyolipoma

China
Novartis Pharmaceuticals

Completed

Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients (4EVERLUNG)

Lung Transplantation

Germany
Novartis Pharmaceuticals

Completed

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

Neuroendocrine Tumors

Germany
Washington University School of Medicine

Completed

Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations

Solid Tumor | Solid Malignancy

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors (RADIANT-3)

Advanced Neuroendocrine Tumors of Pancreatic Origin

Canada, France, United Kingdom, Taiwan, Belgium, Spain, Netherlands, United States, Italy, Sweden, Switzerland, Thailand, Germany, Greece, Korea, Republic of, Japan, Brazil, Slovakia
Erasmus Medical Center
Utrecht University

Unknown

Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex (RAPIT)

Tuberous Sclerosis Complex | TSC Related Cognitive Disability | TSC Related Autism | TSC Related Learning Problems

Netherlands
Mayo Clinic
National Cancer Institute (NCI)

Completed

Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Lymphoma | Leukemia | Lymphoproliferative Disorder

United States
Cardiff University
Novartis

Unknown

A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis (TRON)

Tuberous Sclerosis

United Kingdom
Novartis Pharmaceuticals

Completed

A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor (OSAT)

Metastatic Renal Cell Carcinoma (mRCC)

Norway
Reneo Pharma Ltd

Completed

A Study of the Safety of REN001 in Patients With McArdle Disease

McArdle Disease

Spain, United Kingdom
Reneo Pharma Ltd

Terminated

A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy

Primary Mitochondrial Myopathy

United Kingdom
American College of Radiology Imaging Network
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655)

Colorectal Cancer | Metastatic Cancer

United States
Reneo Pharma Ltd

Terminated

An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead)

Primary Mitochondrial Myopathy

Spain, Australia, Belgium, Denmark, Canada, United Kingdom, France, Germany, Hungary, Italy, Netherlands, New Zealand

Search clinical trials for: RAD001 and MitomycinC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations